Refine by
Biopsy Articles & Analysis: Older
71 articles found
For such critical samples, especially those from diseased human biopsies, high-quality media are required. This reduces the risk of contamination and saves time, labor and money by eliminating required preparation steps and replenishment. ...
Tumor cells from primary or metastatic human cancers collected by surgery or biopsy procedures were transplanted into zebrafish. This approach provides information about the effectiveness of the treatment because the cells share the same molecular, genetic and clinical characteristics as the donor. ...
Discover how matched tumor-normal sequencing can help clinical researchers detect the somatic origin of variants with certainty. In the era of precision oncology, it has become increasingly common for patients diagnosed with cancer to undergo tumor sequencing. Identifying the mutations that make up a tumor’s genomic landscape can help guide selection of targeted therapies and inform ...
Other test methods can include: · Endoscopic biopsies (invasive & costly) · Blood test (repeated every 30 minutes) · Stool acidity test (infants, young children) Home breath testing devices Home breath testing devices were more widely optimised due to the COVID-19 pandemic, to prevent waiting list delays and people felt safer taking ...
In response to the emerging needs in global healthcare, SOPHiA GENETICS has just revealed the New Generation SOPHiA DDM™ Platform, aiming to stay at the forefront of precision medicine and address today the healthcare needs of tomorrow. ...
ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers. The ESMO Precision Medicine Working Group (PMWG) first published its recommendations for when to use next-generation sequencing (NGS) in routine practice for patients with metastatic cancers in 20201. At that time, based ...
Dr. Kate Sasser from Tempus led a discussion on the potential of antibody-drug conjugates (ADCs), their challenges in targeting tumor antigens, and the future of cancer treatment with Dr. Daniel Johnson, Dr. Funda Meric-Bernstam, and Dr. Kellogg Parsons. The oncology field is rapidly advancing with the development of antibody-drug conjugates (ADCs), offering new hope for ...
ByTempus
Contexte Myasthenia gravis (MG) is an autoimmune disease caused by the presence of antibodies directed against components of the muscle membrane located at the neuromuscular junction. In the majority of cases, these are autoantibodies directed against the acetylcholine receptor (AChR). The origin of the autoimmune response is not known, but thymic abnormalities and defective regulation of the ...
Project spearheaded by Singapore’s national Diagnostics Development (DxD) Hub Clinical trial introducing X-ZELL as an additional diagnostic tool Pilot study showed X-ZELL more than 70 per cent reduction in unnecessary biopsies ...
The literature shows that pathologists, being only humans under considerable pressure, may miss cancer in up to 1-3% of prostate biopsies.2,3,4 Considering the over one million men who are diagnosed worldwide per year, this may reflect a large number of patients.5 Moreover, the subjectivity of Gleason grading and tumor quantification can result in difficulty assigning effective ...
Medical History Jane is a 40-year-old, married mother of two teenage boys. She teaches at the local elementary school and has been in good health for most of her life. She has no surgical history. Her most severe ailment up to this point has been the flu at age 27. Her students are first-graders; they are often difficult to control. She also experiences the normal stresses of raising ...
Since the 19th century, the practice of tissue processing has remained largely unchanged, resulting in solidified, paraffin-embedded tissue blocks for sectioning. As staining procedures have advanced and immunohistochemistry is becoming more widely used, high-quality tissue sections are paramount for accurate interpretation of disease ...
At the referring center, previous resection of nodularity revealed Tla adenocarcinoma with negative margins. Subsequent surveillance biopsies yielded IMC, and triggered referral. For the procedures described here, standard endoscopy with the addition of Volumetric Laser Endomicroscopy (VLE). using the NvisionVLE; Imaging System with Real-time Targeting, was performed to localize ...
(Figures 1-3) Pathology of the EMR sample was positive for Adenocarcinoma (Figure 4) A subsequent surveillance ECD showed the previous EMR site, a normal GEJ. and normal distal esophageal lining. Random biopsies were taken of the treated area and were negative for dysplasia. ...
After implementation of AI decision support, the benign biopsy rate decreased from 71.79% to 59.2% while the overall biopsy rate stayed constant. ...
Yale Medicine, an academic medical center with a high volume of prostate biopsies, conducted a study to determine Paige Prostate’s utility as a prescreening tool for clinical use. A total of 1,876 prostate core biopsy slides were analyzed by Paige Prostate, and only those cores categorized by the AI as “suspicious” or as out of distribution were ...
In 1982, two Australian researchers discovered bacteria in an inflamed mucosa from stomach biopsies from a patient’s peptic ulcers. They identified the bacteria as H. pylori. ...
The ClarityDX Prostate® test uses a proprietary machine-learning algorithm that combines data from biological and clinical biomarkers to generate a risk score for clinically significant prostate cancer, defined as Gleason grade group 2 or higher, on prostate biopsy. The ClarityDX Prostate® test is intended to be used as a reflex test for men with elevated levels of PSA ...
PSA test alone could have resulted in 37% fewer unnecessary biopsies. The clinical study recruited men from two sites in Alberta, Canada, and one site in Baltimore, USA. EDMONTON, AB, June 30, 2022 /CNW/ - Nanostics Inc., a precision health diagnostics company, today announces positive data from a pre-biopsy clinical validation study of its ClarityDX ...
These findings support INOVIQ’s SubB2M diagnostics program developing blood tests for monitoring of breast, ovarian and other cancers. Commercialisation of liquid biopsy pipeline INOVIQ CEO Dr Leearne Hinch said: “INOVIQ remains focused on the development and commercialisation of its liquid biopsy pipeline of exosome and SubB2M-based blood tests for ...